Jane Street to resume trading on NSE, BSE from Tuesday
The development follows an update from the Securities and Exchange Board of India late Monday clarifying that Jane Street could resume trading in the country's stock exchanges subject to stipulations laid out in its 3 July interim order, said two people aware of the matter.
Jane Street entities will also be allowed to trade on the highly popular index options segment on both the exchanges provided they abide by Sebi's conditions.
'Jane Street will be allowed to trade on NSE effective Tuesday, per Sebi's directions in its interim order, which precludes them (Jane Street entities) from engaging in any manipulative trades alluded to in the order,' said one of the persons mentioned above.
Sebi in its interim order barred four Jane Street entities for alleged manipulation of indices such as Bank Nifty and Nifty to make ₹ 43,289 crore on index options between January 2023 and March 2025.
Sebi also directed the four Jane Street entities to 'cease and desist from directly or indirectly engaging in any fraudulent, manipulative, or unfair trade practice that may be in breach of its regulations'.
In a statement issued 'Jane Street entities have confirmed that they will comply with this,' the regulator said in a press release issued on Tuesday.
On 11 July, Jane Street deposited ₹ 4,843.5 crore in an escrow account to be able to resume trading in India, as directed by Sebi, although it has hired law firm Khaitan & Co. to contest the regulator's interim order.
Jane Street has said that its trades were in the nature of arbitrage, exploiting price differences in the same underlying index across futures and options on Nifty and Bank Nifty.
'Not all the four entities were active on BSE, but those that were will be enabled to trade on the exchange from tomorrow (Tuesday) under the heightened monitoring surveillance stipulated by Sebi's interim order,' said the person quoted above.
NSE, BSE and Sebi didn't immediately reply to Mint's queries.
Shares of the listed BSE Ltd jumped almost 3% to ₹ 2,521.3 apiece on Monday before the Sebi update. NSE's unlisted shares rose 2.5-5% to ₹ 2,150-2,200, per Narinder Wadhwa, managing director at SKI Capital, who said demand for the shares had spurted.
Mint had reported on 16 July that although Jane Street had met a key requirement to resume operations in Indian markets by depositing over ₹ 4,843 crore, its immediate return to trading wasn't certain amid multiple regulatory hurdles and unprecedented scrutiny.
Legal experts cited in the report had said the deposit only served as a safeguard so the alleged illegal gains don't leave the Indian jurisdiction or get dissipated while the investigation continues.
In a statement on 21 July, Sebi clarified that its interim order barring Jane Street from trading in the securities market shall cease to apply as the quant trading firm had deposited the alleged illegal gains in an escrow account.
Sebi has also directed the stock exchanges to closely monitor any future dealings and positions of Jane Street Group to ensure it does not directly or indirectly indulge in any kind of manipulative activity.
Sebi's probe into Jane Street trading is continuing with a final order expected to take months, per one of the people mentioned above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
17 minutes ago
- Indian Express
India-UK Free Trade Agreement: A $34 billion game-changer for exports and employment
A positive outcome of the tariff saga started by the US is that countries are getting together to sign deals with one another. The Free Trade Agreement (FTA) with the United Kingdom was finalised in May and has been consummated by the signing of the deal. This would be India's biggest deal signed in 10 years and UK's fourth since its exit from the EU. India has signed, with alacrity, a deal with the UK which will raise the total volume of trade to around $34 billion per annum from the present levels of around $2-25 billion. More importantly, it represents the first of many steps undertaken to sign deals with other nations to leverage mutual benefits. The India-UK FTA would eliminate duties on 99 per cent of Indian exports to England. India will gain mainly through higher exports in fish products, chemicals, jewellery, leather products, readymade garments and electronics, which are largely labour-intensive, and will in turn benefit the small and medium enterprises (SMEs) specialising in these products. Intuitively, this will be a boost for not just the SME group per se but also for employment, as such treaties are signed with other countries, too. Units in Tirupur, Surat, Ludhiana, Chennai, and cities in Assam and elsewhere would stand to gain. The present deal seeks to eliminate tariffs on a majority of products that previously faced duties ranging from 4 to 16 per cent. Exports could rise potentially by 20-40 per cent, depending on the responses of the concerned industries. From the UK's point of view, there would be free flow of goods such as automobiles, whisky and gin, among others, which will also help push up employment, thus bringing about symbiotic benefits to both countries. There would be easier access to around 64 per cent of UK's exports to India. Further, as Indian companies invest more as part of the expansion plans in the UK — it can go up to £6 billion — there would be more jobs created which can cross the 20,000 mark. The effective tariff rate for goods from the UK would come down from 15 per cent to 3 per cent, which includes duty on whisky coming down from 150 per cent to 75 per cent immediately and to 40 per cent over a period of 10 years. One area that will work well for India is agriculture, covering various crops as well as fisheries. This includes spices, vegetables, fruits and pulses. As India works to leverage the strength of its agriculture, this FTA provides space for expansion and will take us closer to the target of $100 billion which has been targeted by 2030. At the ground level, there would be streamlining of the sanitary and phytosanitary regulations in the UK, which has hitherto been a major hurdle in the export of farm products. The other significant benefit for us would be in textiles where duty-free exports would be permitted. This is significant as countries like Bangladesh, Pakistan and Cambodia have had the advantage of similar structure, making it tough for our exports, presently in the region of just $1.5 billion. This comes at an opportune time when there could be other pressures on our textile exports to the US. A similar gain can be seen in the case of engineering, where our exports were just $3.7 billion to the UK, which imports as much as $195-200 billion from the world. With the free trade agreement in place, it should be possible to double our exports to the UK. Similar benefits can be seen in pharma, electronics, software, jewellery, etc. In fact, the NHS would start to use generics manufactured by India — a big boost to the industry. At the individual level, there has also been a deal on allowing Indians to work in the UK on a temporary basis with fewer pressures on paying for social security being one of the main gains. Indians would gain from cheaper import of higher-end cars as well as chocolates and whisky, with the duties coming down substantially, thus making them more affordable. How can this deal be viewed? First, it is something which provides a thrust to our exports and hence employment. Second, furthering relations with the UK opens the door to negotiate with other nations and the EU should be next on the radar. Third, such a deal also provides a template to be followed when it comes to negotiating one with the US, already in the discussion stage. Fourth, the deal has focused on an entire array of goods and while manufacturing always looked to be on the cards, the fact that agriculture has a lot to gain is significant as we are harnessing the strength built in this sector. This will help to make the sector more commercial and farming more remunerative as such deals are struck with other nations. Finally, this deal reflects the government's strong commitment to boosting exports as part of its broader effort to integrate the Indian economy into global supply chains. The writer is chief economist, Bank of Baroda, and author of Corporate Quirks: The Darker Side of the Sun. Views are personal
Mint
17 minutes ago
- Mint
Delhi-based venture capital fund raises stake in this LIC-owned NBFC stock. Check details
LIC-owned stock: Shares of Paisalo Digital snapped their three-day winning run on Friday, July 25, even as Equilibrated Venture CFlow acquired a stake in the company. The selloff in the Indian stock market and profit booking after a stellar run over the last few days likely promoted a decline in the small-cap stock, which is part of Life Insurance Corporation of India's (LIC) portfolio. According to a filing shared by Paisalo Digital, the Delhi-based venture capitalist Equilibrated Venture CFlow acquired 74,70,000 shares of the company via the open market, representing a 0.82% stake. The stake was acquired by the company on July 24 and July 25, as per the filing. With this, Equilibrated Venture CFlow's stake in the LIC-owned NBFC stock rose to 16.50% from 15.67% earlier. According to the latest shareholding pattern filed by the company earlier this month, LIC owns a 1.12% stake or 77,59,511 shares. Another PSU life insurer, SBI Life Insurance, holds an 8.96% stake. The small-cap NBFC stock also remained in focus this entire week following the announcement of its Q1 results for FY26 and dividend record date.
&w=3840&q=100)
Business Standard
17 minutes ago
- Business Standard
Smallcap stock soars 14% on heavy volumes, nears record high. Do you own?
Vimta Labs share price today: Shares of Vimta Labs have moved higher by 14 per cent to ₹578 on the BSE in Friday's intra-day trade amid heavy volumes in otherwise a weak market. The stock price of smallcap company is trading close to its record high level of ₹591.50 touched on February 12, 2025. In the past six trading days, the stock rallied 24 per cent. At 12:50 PM; Vimta Labs was quoting 13 per cent higher at ₹572, as compared to 0.7 per cent decline in the BSE Sensex. The average trading volumes on the counter jumped over five-fold. A combined 5.62 million equity shares representing 12.62 per cent of total equity of Vimta Labs have changed hands on the NSE (5.16 million shares) and BSE (0.46 million shares). Vimta Labs clarification on increase in volume of the shares Vimta Labs assumes that the movement in the share price of the company is purely due to market factors and not specifically related to the company. On July 21, the company has informed stock exchange that it has made all necessary prompt disclosures within the stipulated timelines and has not withheld any events/information/announcement (including impending announcement) including any price sensitive information that may have a bearing on the operation/performance of the company or on the price behaviour in the scrip. Vimta Labs Q1FY26 results In April to June 2025 quarter (Q1FY26), Vimta Labs reported revenue of ₹99.3 crore, up 31.4 per cent year-on-year (Y-o-Y), which was driven by pharmaceutical & food contract research and testing services. Profit after tax increased 35.9 per cent Y-o-Y to ₹18.9 crore from ₹13.9 crore in a year ago quarter. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) margin improved to 35.7 per cent from 35.2 per cent. Vimta completed a successful United States Food and Drug Administration (USFDA) Good Clinical Practice (GCP) inspection with zero Form 483 observations and received a letter of cGMP compliance from ANSM (EMA) during the quarter. Vimta Labs company outlook Vimta Labs is positive about its growth prospects in clinical, pre-clinical, non-clinical, biopharmaceutical, pharma analytical, and electronics & electrical contract testing and research, all of which have a strong positive outlook despite the current global economic uncertainties, large competition, and stricter regulatory compliance requirements. The company has a strong customer base, and promising pipelines, which give it good visibility of growth over the medium term. Over the long term, the company expects it will strategically look at acquisition opportunities or alliances or partnerships to enhance its market reach, capabilities and service portfolio, to gain further market share. Vimta Labs, in its FY25 annual report, said that the trend in growth of the overseas market for the company is positive going forward. The domestic market continues to hold immense potential led by economic growth in the country. However, inflationary pressures in terms of cost of manpower, technology and material, and pricing pressures due to proliferation of laboratories in the country could be a risk to watch out for, the company said. About Vimta Labs Vimta Labs is a leading contract research and testing organisation, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.
